RxDoctor Payments Data

Heather Morgan, MD

Geriatric Medicine · Omaha, NENPI 1922013531

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $6,600 of the $8,577 with a category attached, or 77.0%. Every reported general payment came from a single manufacturer, Lilly USA, LLC. Reporting peaked in 2022 at $7,930 and has fallen 92.4% since, to $605 in 2025. Among geriatric medicine clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,577in general payments, 2019–2025

Across 24 payments — averaging $357.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$9K

What the payments were for

  • Speaking & faculty fees$6,60077%
  • Travel & lodging$1,62519%
  • Food & beverage$3524%

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC24$8,577

How this compares

$8,577 in reported general payments places this provider in the 95th percentile of 21 geriatric medicine providers in Nebraska.

See all geriatric medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$304,280
Medicare patients
545
Services billed
8,081

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban182$147,418
TrulicityDulaglutide58$69,819
OzempicSemaglutide44$42,571
MyrbetriqMirabegron73$38,192
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$25,069
RestasisCyclosporine46$16,118
MounjaroTirzepatide16$15,429
XareltoRivaroxaban17$13,396
Breo ElliptaFluticasone/Vilanterol29$12,918
JanuviaSitagliptin Phosphate11$11,774
Potassium Chloride214$9,541
LinzessLinaclotide15$9,475
Memantine Hcl193$6,800
Omeprazole357$5,942
Atorvastatin Calcium535$5,444

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$8,577$85,24874 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 21 geriatric medicine providers in Nebraska.

Other geriatric medicine in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →